top of page

KLUS Pharma is Attending BIO Partnering at JPM 2023!

KLUS Pharma is Attending BIO Partnering @ JPMorgan Healthcare Conference in San Francisco, CA (January 9-12, 2023).

KLUS Pharma will attend the annual BIO Partnering @ JPM held in San Francisco, CA. KLUS Pharma is the US subsidiary of Kelun-Biotech, a mid-sized innovative biopharma company based in Chengdu, China. Kelun-Biotech is advancing a broad pipeline of small molecules, monoclonal antibodies, antibody drug conjugates (ADCs), and cell therapies for the treatment of cancer, autoimmune, metabolic, and cardiovascular diseases. With over ten clinical-stage assets and dozens of promising preclinical candidates, we are actively seeking strategic partners to help accelerate the global development of these promising therapeutic candidates. In addition, we are also seeking in-licensing opportunities for the Greater China market, including innovative therapeutics in oncology, autoimmune, metabolic, and cardiovascular diseases areas. Clinical-stage assets with preliminary safety and efficacy data are preferred. We also consider selective generic products suitable for the China market in the following therapeutic spaces: neurology, infectious disease, reproductive health, and fertility treatments.

Attending BIO Partnering during JPMorgan Healthcare Conference Week? Click the link below to request a meeting with KLUS Pharma through the BIO partnering system! #JPM2023

We look forward to meeting new potential partners at the event!

Business Development Team, KLUS Pharma

Monday, November 14, 2022

bottom of page